Laboratorios Rovi : Risvan’s US launch aborted. Dull FY25 guidance offsets a strong Q3
>Clarifying foreword - Please note that the company filed a first English version of its Q3 results release with the Spanish market watchdog (CNMV) in which it stated the following: ‘Finally, having obtained marketing authorisation for Risvan® from the FDA (Food and Drug Administration), ROVI expects to start marketing the product on the United States market, probably through a partner. Although the potential sales that this product will reach in 2025 were taken into ...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.